View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 20, 2022

Capricor doses first subject in Phase III Duchenne muscular dystrophy trial

The double-blind, randomised, placebo-controlled trial will enrol nearly 70 subjects in the US.

Capricor Therapeutics has dosed the first subject in the Phase III HOPE-3 clinical trial of cell therapy, CAP-1002, to treat late-stage Duchenne muscular dystrophy (DMD).

CAP-1002 comprises allogeneic cardiosphere-derived cells (CDCs), a kind of progenitor cell. 

The double-blind, randomised, placebo-controlled trial will enrol nearly 70 subjects in the US. 

Trial subjects will be categorised into a 1:1 ratio to receive either CAP-1002 or placebo. 

Patients in the active arm will be given 150 million CDCs (CAP-1002) intravenously every three months for a total of four doses.

The Performance of the Upper Limb (PUL) 2.0, with a conceptual framework indicating weakness progression in upper limb function will be the trial’s primary outcome measure. 

An established tool, PUL is intended to evaluate high (shoulder), mid (elbow) and distal (wrist and hand) function.

Various other secondary endpoints including cardiac function analyses will also be measured in the trial.

Recently, the company collaborated with Nippon Shinyaku which holds the marketing and distribution rights in the US. 

Outside the US, Capricor holds global commercial rights to the cell therapy.

This collaboration offers funding for HOPE-3 and other potential milestone-based payments to back CAP-1002’s clinical development for DMD.

Capricor Therapeutics CEO Linda Marbán said: “The data from our Phase II clinical trial suggest that CAP-1002 can slow loss of function by as much as 70% in terms of upper limb skeletal muscle function. 

“Since there are very limited therapeutic options for these patients and CAP-1002 has been shown to be safe and effective, we are pleased to begin this pivotal trial with the goal of achieving regulatory approval as quickly as possible.”

A genetic disorder, DMD is characterised by progressive weakness and chronic skeletal, heart and respiratory muscle inflammation.

In March this year, the company reported topline data from the Phase II INSPIRE trial of CAP-1002 to potentially treat severe Covid-19 in hospitalised patients.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena